$9.45
0.64% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Theravance Biopharma Inc Stock price

$9.45
+0.32 3.50% 1M
-0.52 5.22% 6M
+0.04 0.43% YTD
+0.35 3.85% 1Y
+0.71 8.12% 3Y
-17.22 64.57% 5Y
-4.79 33.64% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.06 0.64%
ISIN
KYG8807B1068
Symbol
TBPH
Sector
Industry

Key metrics

Market capitalization $472.51m
Enterprise Value $420.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 13.03
EV/Sales (TTM) EV/Sales 6.45
P/S ratio (TTM) P/S ratio 7.24
P/B ratio (TTM) P/B ratio 2.85
Revenue growth (TTM) Revenue growth 6.11%
Revenue (TTM) Revenue $65.27m
EBIT (operating result TTM) EBIT $-45.66m
Free Cash Flow (TTM) Free Cash Flow $32.29m
Cash position $130.86m
EPS (TTM) EPS $-1.19
P/E forward negative
P/S forward 5.25
EV/Sales forward 4.67
Short interest 12.60%
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Theravance Biopharma Inc forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
50%
Hold
50%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
65 65
6% 6%
100%
- Direct Costs 5.86 5.86
1% 1%
9%
59 59
7% 7%
91%
- Selling and Administrative Expenses 61 61
5% 5%
93%
- Research and Development Expense 39 39
16% 16%
59%
-40 -40
13% 13%
-61%
- Depreciation and Amortization 5.86 5.86
1% 1%
9%
EBIT (Operating Income) EBIT -46 -46
11% 11%
-70%
Net Profit -58 -58
30% 30%
-89%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
8 days ago
DUBLIN , May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
Neutral
Seeking Alpha
10 days ago
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial officer Aine Miller - Head-Development Conference Call Participants Marc Frahm - TD Cowen Operator Hello, ladies and gentlemen. Good afternoon.
Neutral
PRNewsWire
12 days ago
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massach...
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 97
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today